Clinical InvestigationInterventional CardiologyComparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: Intravascular ultrasound results from ENDEAVOR III
Section snippets
Patients
Data were derived from the Endeavor Drug-Eluting Coronary Stent System Versus the Center Siromlimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ENDEAVOR) III trial, a multicenter, single-blind, parallel, 2-arm, randomized control study comparing the efficacy between ZES and SES for the treatment of de novo coronary artery lesions.1 Patients were randomized to either ZES or SES in a 3:1 fashion. The study protocol was approved by the institutional review board at
Study population and patient characteristics
Intravascular ultrasound images were obtained in 296 cases (ZES 222, SES 74) at 8-month follow-up analysis, with 258 cases (ZES 190, SES 68) available for serial (baseline and 8-month follow-up) analysis. Because of inconsistent pullback or inadequate image quality, 48 cases (ZES 35, SES 13) were excluded from volumetric analysis. Patient, lesion, and procedural characteristics are shown in Table I. Except for the higher percentage of men and the lower maximum balloon pressure in the ZES group,
Discussion
This IVUS analysis has shown that ZES had greater amount of neointima compared with SES. Zotarolimus-eluting stents also showed larger IVUS-detectable neointimal coverage over stent surface evenly distributed throughout its length and lower incidence of late-acquired ISA.
References (15)
- et al.
Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial
J Am Coll Cardiol
(2006) - et al.
Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis
J Am Coll Cardiol
(2005) - et al.
Intimal hyperplasia thickness at follow-up is independent of stent size: a serial intravascular ultrasound study
Am J Cardiol
(1998) - et al.
Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial
J Am Coll Cardiol
(2005) - et al.
Intravascular ultrasound assessment of neointima distribution and the length of stent that was free of intravascular ultrasound–detectable intimal hyperplasia in paclitaxel-eluting stents
Am J Cardiol
(2005) - et al.
Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk
J Am Coll Cardiol
(2006) - et al.
7-hexanoyltaxol–eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE)
Circulation
(2002)
Cited by (80)
Longitudinal Neointimal Distribution Pattern After Everolimus-Eluting Stent Implantation: Insights From Optical Coherence Tomography Study
2021, Cardiovascular Revascularization MedicineMedical Device Technologies: A Systems Based Overview Using Engineering Standards
2020, Medical Device Technologies: A Systems Based Overview Using Engineering StandardsRelative dose and vascular response after drug-eluting stent implantation: A dosimetric 3D-intravascular ultrasound study
2016, International Journal of CardiologyDrug-eluting biostable and erodible stents
2014, Journal of Controlled ReleaseEvolving management of patients treated by drug-eluting stent: Prevention of late events
2014, Cardiovascular Revascularization Medicine
Drs. Miyazawa and Ako contributed equally to this work.
This study was supported by Medtronic Inc, Santa Rosa, CA.